Your browser doesn't support javascript.
[Convalescent Plasma for Treatment of Severe COVID-19: Rationale and Designing of a Randomized, Open-Label Clinical Trial of Convalescent Plasma Compared to Best Supportive Care (CAPSID Trial)]
Non-conventional in German | WHO COVID | ID: covidwho-740044
ABSTRACT
Convalescent plasma therapy was administered in patients with acute, viral respiratory disorders with severe clinical course (SARS- or MERS coronavirus, influenza H1N1, H5N1). These studies suggested that convalescent plasma is likely to improve viral clearance, reduce the length of hospital stay and reduce mortality and appeared to be safe. However, since controlled randomized trials were lacking only low-quality evidence was available. Most patients mount a strong humoral immune response early in the course of a SARS-CoV-2 infection, including neutralizing antibodies. Due to the pandemic an increasing number of convalescent patients who are potential donors for SARS-CoV-2 convalescent plasma will be available. We designed a prospective randomized clinical trial to study the safety and efficacy of convalescent plasma for treatment of severe COVID-19 and its mechanism of action (CAPSID trial). Here we present the rationale for this trial and major aspects of the study outline.
Full text: Available Collection: Databases of international organizations Database: WHO COVID Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: German Document Type: Non-conventional

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Databases of international organizations Database: WHO COVID Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: German Document Type: Non-conventional